Logo

SBFM

Sunshine Biopharma, Inc.

SBFM

Sunshine Biopharma, Inc. • NASDAQ
$1.43 ▲ 2.14% (+0.03)
Market Cap $7.02 M
52w High $3.90
52w Low $1.17
Dividend Yield 0%
P/E 0.27
Volume 600
Outstanding Shares 4.91M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $9.41M ▲ $5.478M ▲ $-1.771M ▼ -18.818% ▼ $-7.8 ▼ $-1.907M ▼
Q1-2025 $8.901M ▼ $4.026M ▼ $-1.18M ▲ -13.257% ▲ $-0.44 ▲ $-1.155M ▲
Q4-2024 $9.595M ▲ $5.131M ▲ $-2.158M ▼ -22.491% ▼ $-0.84 ▲ $-2.213M ▼
Q3-2024 $8.435M ▼ $3.973M ▲ $-1.198M ▼ -14.203% ▼ $-0.94 ▲ $-918K ▼
Q2-2024 $9.303M $3.574M $-494K -5.31% $-9.94 $-787K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $9.306M ▼ $31.487M ▼ $7.288M ▲ $24.199M ▼
Q2-2025 $10.305M ▲ $31.965M ▲ $6.28M ▼ $25.685M ▲
Q1-2025 $8.195M ▼ $29.187M ▼ $6.485M ▼ $22.702M ▼
Q4-2024 $9.687M ▼ $30.56M ▲ $7.06M ▲ $23.501M ▼
Q3-2024 $12.207M $30.057M $5.018M $25.039M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-1.771M ▼ $-1.273M ▲ $-491.778K ▼ $3.61M ▲ $2.181M ▲ $-1.824M ▲
Q1-2025 $-1.18M ▲ $-1.714M ▲ $-176.024K ▲ $338.137K ▼ $-1.562M ▲ $-1.926M ▲
Q4-2024 $-2.158M ▼ $-3.407M ▼ $-531.535K ▲ $2.054M ▲ $-2.52M ▼ $-3.847M ▼
Q3-2024 $-1.198M ▼ $-1.361M ▲ $-578.368K ▼ $1.866M ▲ $698.91K ▲ $-1.878M ▲
Q2-2024 $-494.3K $-4.578M $-542.208K $-28.583K $-5.926M $-5.15M

Five-Year Company Overview

Income Statement

Income Statement Sunshine Biopharma is still operating at a very small scale. Revenue exists but remains minimal, and the core business is not yet profitable. Gross profit is positive but tiny, and operating expenses continue to exceed that profit, leading to recurring net losses. The pattern over the last few years is one of ongoing investment and development rather than a mature, earnings-driven company. Large swings in reported earnings per share mainly reflect share structure changes rather than dramatic shifts in the underlying business performance.

Balance Sheet

Balance Sheet The balance sheet is very light, with a small base of total assets and cash and only modest equity. On the positive side, the company shows no financial debt, which reduces balance sheet risk from lenders. On the other hand, the limited asset and cash base highlights the company’s small size and the constrained resources available to fund research, operations, and growth. Overall, financial strength appears thin, typical of an early-stage biotech, and leaves little buffer against setbacks or delays.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, which means the business is not self-funding and continues to consume cash. Free cash flow is also negative, though capital spending appears modest. This suggests the main cash use is salaries, R&D, and general operating costs rather than heavy investment in facilities. The company likely relies on issuing shares or other external funding to bridge the gap. Sustaining the pipeline and commercial activities will depend on continued access to new capital or a meaningful improvement in operating cash generation.

Competitive Edge

Competitive Edge Sunshine Biopharma combines a small Canadian generics and biosimilars platform with a higher-risk, higher-potential proprietary drug pipeline. This diversification is a relative strength: generics and biosimilars can offer more predictable, shorter-term revenue, while oncology and antiviral drugs, if successful, can create substantial upside. However, the company competes in crowded and demanding markets. Generics and biosimilars face intense price pressure and strong incumbents, while oncology and antiviral innovation pits Sunshine against much larger and better-funded players. Intellectual property protection and the integrated manufacturing and distribution capabilities provide some differentiation, but the company’s small scale and early stage in the clinic limit its current competitive weight.

Innovation and R&D

Innovation and R&D R&D is the centerpiece of the story. The company is pursuing three distinct programs: an anti-cancer small molecule designed to tackle drug-resistant tumors, an mRNA-based therapy for liver cancer, and an antiviral targeting a key coronavirus enzyme. These are scientifically ambitious projects in areas of genuine unmet medical need, and the company holds patent protection on key assets. Collaborations with academic partners add credibility and technical depth. At the same time, all of these programs appear to be early in development, which means long timelines, high scientific and regulatory risk, and substantial funding needs before any potential commercial payoff. Progress through preclinical studies and into human trials will be critical milestones to watch.

Summary

Overall, Sunshine Biopharma looks like a very early-stage, high-risk biotechnology story wrapped inside a small generics and biosimilars business. Financially, it remains loss-making with limited assets and ongoing cash burn, but without the complication of financial debt. The strategic idea—using generics and biosimilars to help support a proprietary pipeline—has logic, yet today both sides of the business are still small in absolute terms. The key opportunities lie in advancing its oncology and antiviral candidates into and through clinical trials, and in scaling the Nora Pharma generics and biosimilars portfolio to a more meaningful level. The main risks center on funding, clinical and regulatory uncertainty, intense competition, and the company’s very limited financial cushion. This is best viewed as an early, speculative development platform rather than a mature operating business at this stage.

NEWS

October 28, 2025 · 2:10 PM UTC

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Read more

October 28, 2025 · 7:45 AM UTC

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Read more

October 20, 2025 · 7:45 AM UTC

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Read more

October 16, 2025 · 7:45 AM UTC

Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin

Read more

October 14, 2025 · 10:45 AM UTC

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

Read more